Identification

Name
Panitumumab
Accession Number
DB01269
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Panitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.

Protein structure
Db01269
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • ABX-EGF
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
VectibixSolution400 mg/20mLIntravenousAmgen2006-10-10Not applicableUs
VectibixSolution200 mg/10mLIntravenousAmgen2006-10-102017-07-27Us
VectibixInjection, solution, concentrate20 mg/mlIntravenousAmgen Europe B.V.2007-12-03Not applicableEu
VectibixSolution200 mgIntravenousAmgenNot applicableNot applicableCanada
VectibixSolution100 mg/5mLIntravenousAmgen2006-10-10Not applicableUs
VectibixInjection, solution, concentrate20 mg/mlIntravenousAmgen Europe B.V.2007-12-03Not applicableEu
VectibixSolution100 mgIntravenousAmgen2008-05-27Not applicableCanada
VectibixSolution400 mgIntravenousAmgen2017-01-03Not applicableCanada
VectibixInjection, solution, concentrate20 mg/mlIntravenousAmgen Europe B.V.2007-12-03Not applicableEu
Categories
UNII
6A901E312A
CAS number
339177-26-3

Pharmacology

Indication

For the treatment of EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.

Structured Indications
Pharmacodynamics

Panitumumab is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human Epidermal Growth Factor Receptor (EGFR). EGFR is a transmembrane glycoprotein that belongs to the subfamily of type I receptor tyrosine kinases. Although EGFR is expressed in normal cells, the overexpression of EGFR is detected in many human cancers, including those of the colon and rectum. Interaction of EGFR with its normal ligands causes phosphorylation and activation of a series of intracellular proteins that will in turn regulate the transcription of genes involved with cellular growth and survival, motility, and prolieration. Signal transduction through EGFR leads to the activation of the wild type KRAS gene, but the presence of an activating somatic mutation of the KRAS gene within a cancer cell can result in the dysregulation of signaling pathways and resistance to EGFR inhibitor therapy.

Mechanism of action

Panitumumab binds specifically to EGFR on both normal and tumor cells, and competitively inhibits the binding of ligands for EGFR. Nonclinical studies show that binding of panitumumab to the EGFR prevents ligand-induced receptor autophosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased pro-inflammatory cytokine and vascular growth factor production, and internalization of the EGFR.

TargetActionsOrganism
AEpidermal growth factor receptor
suppressor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

7.5 days (range: 4-11 days)

Clearance
  • 4.9+/- 1.4 mL/kg/day [Following single-dose administrations of panitumumab as 1-hour infusions]
Toxicity

Panitumumab was shown to cause skin, ocular and mucosal related toxicities in 90% of patients receiving panitumumab. Subsequent to the development of severe dermatologic toxicities, infectious complications, including sepsis, septic death, and abscesses requiring incisions and drainage, were reported.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Panitumumab Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Panitumumab.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Panitumumab.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Panitumumab.Investigational
BelimumabThe risk or severity of adverse effects can be increased when Panitumumab is combined with Belimumab.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Panitumumab.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Panitumumab.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Panitumumab.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Panitumumab.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Panitumumab.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Panitumumab.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Panitumumab.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Panitumumab.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Panitumumab.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Panitumumab.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Panitumumab.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Panitumumab.Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Panitumumab.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Panitumumab.Experimental
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Panitumumab.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Panitumumab.Approved, Withdrawn
INGN 201The therapeutic efficacy of INGN 201 can be decreased when used in combination with Panitumumab.Investigational
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Panitumumab.Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Panitumumab.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Panitumumab.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Panitumumab.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Panitumumab.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Panitumumab.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Panitumumab.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Panitumumab.Experimental
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Panitumumab.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Panitumumab.Investigational
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Panitumumab.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Panitumumab.Approved
Salmonella typhi ty21a live antigenThe therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Panitumumab.Approved
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Panitumumab.Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Panitumumab.Investigational
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Panitumumab.Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Panitumumab.Approved, Investigational
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Zoster vaccine can be decreased when used in combination with Panitumumab.Approved
Yellow fever vaccineThe therapeutic efficacy of Yellow fever vaccine can be decreased when used in combination with Panitumumab.Approved
Food Interactions
Not Available

References

General References
  1. Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM: Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90. [PubMed:14967460]
  2. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001 Apr;38(1):17-23. [PubMed:11255078]
  3. Wu M, Rivkin A, Pham T: Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther. 2008 Jan;30(1):14-30. doi: 10.1016/j.clinthera.2008.01.014. [PubMed:18343240]
  4. Saadeh CE, Lee HS: Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer. Ann Pharmacother. 2007 Apr;41(4):606-13. Epub 2007 Mar 13. [PubMed:17355997]
  5. Keating GM: Panitumumab: a review of its use in metastatic colorectal cancer. Drugs. 2010 May 28;70(8):1059-78. doi: 10.2165/11205090-000000000-00000. [PubMed:20481659]
External Links
UniProt
P01859
PubChem Substance
46505063
ChEMBL
CHEMBL1201827
Therapeutic Targets Database
DNC000135
PharmGKB
PA162373091
Drugs.com
Drugs.com Drug Page
Wikipedia
Panitumumab
ATC Codes
L01XC08 — Panitumumab
AHFS Codes
  • 10:00.00 — Antineoplastic Agents

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableTumors, Solid1
1CompletedTreatmentColorectal Cancers1
1CompletedTreatmentColorectal Cancers / Esophageal Cancers / Lung Cancers / Malignant Neoplasm of Pancreas / Prostate Cancer / Renal Cancers1
1CompletedTreatmentMalignant Neoplasm of Colon / Rectal Carcinoma1
1CompletedTreatmentMetastatic Colorectal Cancers1
1CompletedTreatmentOncology / Tumors / Tumors, Solid1
1CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1CompletedTreatmentTumors, Solid1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1RecruitingTreatmentColorectal Cancers1
1TerminatedTreatmentEsophageal Cancers / Lung Cancers / Malignant Neoplasm of Pancreas1
1TerminatedTreatmentKRAS and NRAS Wild-type Colorectal Cancer1
1, 2Active Not RecruitingTreatmentColorectal Cancers1
1, 2Active Not RecruitingTreatmentMetastatic Colorectal Cancers1
1, 2CompletedOtherMetastatic Colorectal Cancers1
1, 2CompletedTreatmentCancer of the Esophagus1
1, 2CompletedTreatmentCancers1
1, 2CompletedTreatmentCarcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal1
1, 2CompletedTreatmentColorectal Cancers / Gastrointestinal Cancers / Malignant Neoplasm of Colon / Metastatic Colorectal Cancers / Rectal Carcinoma1
1, 2CompletedTreatmentColorectal Cancers / Malignant Neoplasm of Colon / Metastatic Colorectal Cancers / Oncology / Rectal Carcinoma1
1, 2CompletedTreatmentColorectal Cancers / Neoplasms, Colorectal1
1, 2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers1
1, 2CompletedTreatmentMalignant Neoplasm of Pancreas1
1, 2RecruitingTreatmentAnus / Squamous Cell Carcinoma (SCC)1
1, 2RecruitingTreatmentColorectal Cancers / Metastatic Colorectal Cancers / RAS Wild Type Colorectal Cancer / Refractory Colorectal Cancer1
1, 2TerminatedTreatmentAdenocarcinoma Of Esophagus / Gastric Adenocarcinoma1
1, 2TerminatedTreatmentColorectal Cancers1
2Active Not RecruitingTreatmentBiliary Cancer / Cholangiocarcinomas1
2Active Not RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentCancers1
2Active Not RecruitingTreatmentCancers / Carcinoma NOS / Head and Neck Carcinoma / Metastases / Metastatic Cancers / Metastatic or Recurrent Squamous Cell Carcinoma of Head and Neck / Oncology / Squamous Cell Carcinoma (SCC) / Tumors1
2Active Not RecruitingTreatmentColorectal Cancers2
2Active Not RecruitingTreatmentGastroesophageal Junction Neoplasms / Stomach Neoplasms1
2Active Not RecruitingTreatmentGastrointestinal Cancers1
2Active Not RecruitingTreatmentLung Cancers1
2Active Not RecruitingTreatmentMalignant Neoplasm of Esophagus / Malignant Neoplasm of Stomach1
2Active Not RecruitingTreatmentMetastatic Cancers1
2Active Not RecruitingTreatmentMetastatic Colorectal Cancers1
2Active Not RecruitingTreatmentRectal Carcinoma1
2Active Not RecruitingTreatmentRecurrent Colorectal Carcinoma / Stage IVA Colorectal Cancer / Stage IVB Colorectal Cancer1
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers1
2CompletedTreatmentAdenocarcinomas / Esophageal Cancers / Gastro-esophageal Junction Cancer / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentAdvanced Head and Neck Squamous Cancer1
2CompletedTreatmentAdvanced Renal Cell Carcinoma1
2CompletedTreatmentAdvanced Renal Cell Carcinoma / Colorectal Cancers / Lung Cancer Non-Small Cell Cancer (NSCLC) / Prostate Cancer / Tumors, Solid1
2CompletedTreatmentBiliary Tract Cancer / Gallbladder Cancer1
2CompletedTreatmentCancer of Head / Cancer of Head and Neck / Cancer of Neck / Cancer of the Head / Cancer of the Neck / Cancers of the Head and Neck / Head and Neck Carcinoma / Head Cancer / Head, Neck Neoplasms / Neck Cancer / Neoplasms, Head / Neoplasms, Head and Neck / Neoplasms, Neck / Neoplasms, Upper Aerodigestive Tract / UADT Neoplasms1
2CompletedTreatmentCancers / Colorectal Cancers / Malignant Neoplasm of Colon / Metastatic Cancers / Metastatic Colorectal Cancers / Oncology / Rectal Carcinoma1
2CompletedTreatmentCancers / Colorectal Cancers / Malignant Neoplasm of Colon / Metastatic Cancers / Metastatic Colorectal Cancers / Rectal Carcinoma1
2CompletedTreatmentCancers / Head and Neck Carcinoma / Oncology / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentCarcinoma NOS / Colorectal Cancers1
2CompletedTreatmentCholangiocarcinomas3
2CompletedTreatmentColorectal Cancers9
2CompletedTreatmentColorectal Cancers / Hepatic Metastases1
2CompletedTreatmentColorectal Cancers / Malignant Neoplasm of Colon / Metastatic Colorectal Cancers / Rectal Carcinoma1
2CompletedTreatmentColorectal Cancers / Malignant Neoplasm of Colon / Metastatic Colorectal Cancers / Skin Rash / Skin Toxicities1
2CompletedTreatmentColorectal Cancers / Metastases1
2CompletedTreatmentColorectal Cancers / Metastatic Cancers1
2CompletedTreatmentEsophageal Cancers1
2CompletedTreatmentHead and Neck Carcinoma / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC) / Lung Cancers / Neoplasms Metastasis2
2CompletedTreatmentMalignant Neoplasm of Colon1
2CompletedTreatmentMalignant Neoplasm of Pancreas2
2CompletedTreatmentMetastatic Breast Cancer (MBC)1
2CompletedTreatmentMetastatic Colo-rectal Cancer1
2CompletedTreatmentMetastatic Colorectal Cancers6
2CompletedTreatmentMetastatic or Recurrent Squamous Cell Carcinoma of Head and Neck1
2CompletedTreatmentOvarian Epithelial Cancer1
2CompletedTreatmentPathological Response Rate1
2CompletedTreatmentProstate Cancer2
2CompletedTreatmentRectal Carcinoma1
2CompletedTreatmentSquamous Cell Carcinoma of Head and Neck1
2CompletedTreatmentStage IV Colorectal Cancer1
2Not Yet RecruitingTreatmentCarcinoma, Colorectal / Metastatic Colorectal Cancers / Neoplasms Metastasis / Neoplasms, Colorectal1
2Not Yet RecruitingTreatmentColorectal Cancers1
2Not Yet RecruitingTreatmentMetastatic Colorectal Cancers / MSI1
2Not Yet RecruitingTreatmentMetastatic Colorectal Cancers1
2RecruitingTreatmentAdvanced Colorectal Cancer1
2RecruitingTreatmentBRAF Wildtype / Colorectal Cancers / KRAS Wildtype / NRAS Wildtype1
2RecruitingTreatmentCancer, Breast1
2RecruitingTreatmentCancers / Neoplasia / Neoplasms / Tumors1
2RecruitingTreatmentColorectal Adenocarcinoma Metastatic to the Liver1
2RecruitingTreatmentColorectal Cancers1
2RecruitingTreatmentElderly Metastatic Colorectal Cancer Patients1
2RecruitingTreatmentMalignant Neoplasm of Breast1
2RecruitingTreatmentMetastatic Colorectal Cancers4
2RecruitingTreatmentMucinous Adenocarcinoma of the Colon / Mucinous Adenocarcinoma of the Rectum / Recurrent Colon Cancer / Recurrent Rectal Cancer / Signet Ring Adenocarcinoma of the Colon / Signet Ring Adenocarcinoma of the Rectum / Stage IV Colon Cancer / Stage IV Rectal Cancer1
2RecruitingTreatmentRectal Carcinoma1
2SuspendedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2TerminatedTreatmentAdenocarcinoma of the Distal Esophagus / Adenocarcinoma of the Proximal Stomach / Adenocarcinomas of the Gastroesophageal Junction / Gastroesophageal Adenocarcinoma1
2TerminatedTreatmentBladder Cancers1
2TerminatedTreatmentCancer of Pancreas / Cancer of the Pancreas / Malignant Neoplasm of Pancreas1
2TerminatedTreatmentCancer, Breast / Recurrent Breast Cancer / Stage IV Breast Cancer1
2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cancer1
2TerminatedTreatmentCarcinoma of Anal Canal1
2TerminatedTreatmentCarcinoma, Colorectal1
2TerminatedTreatmentColorectal Cancers1
2TerminatedTreatmentHepatic Metastases / KRAS Wild Type Colorectal Cancer / Metastatic Colorectal Cancers1
2TerminatedTreatmentIrresectable Squamous Cell or Adenocarcinoma of the Oesophagus1
2TerminatedTreatmentKRAS Wild Type / Resectable Type II Gastric Adenocarcinoma1
2TerminatedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2TerminatedTreatmentMalignant Glioma of Brain1
2TerminatedTreatmentMetastatic Colorectal Cancers1
2TerminatedTreatmentNeoplasms, Colorectal1
2TerminatedTreatmentRectal Carcinoma1
2TerminatedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2TerminatedTreatmentUrinary Bladder Cancer1
2Unknown StatusTreatmentAdenocarcinoma of the Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Stage II Esophageal Cancer1
2Unknown StatusTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma1
2Unknown StatusTreatmentAfter Resection of Liver Metastases / Colorectal Cancers / KRAS Wildtype1
2Unknown StatusTreatmentAnal Squamous Cell Carcinoma1
2Unknown StatusTreatmentCancer, Ovarian1
2Unknown StatusTreatmentCervical Cancers1
2Unknown StatusTreatmentColorectal Cancers3
2Unknown StatusTreatmentHead and Neck Carcinoma1
2Unknown StatusTreatmentMetastatic Colorectal Cancers2
2Unknown StatusTreatmentSquamous Cell Carcinoma (SCC)1
2WithdrawnTreatmentAdenoma, Pleomorphic / Mixed Salivary Gland Tumor / Salivary Gland Tumor, Mixed / Syringoma, Chondroid1
2WithdrawnTreatmentCarcinoid Syndrome1
2WithdrawnTreatmentHead and Neck Carcinoma1
2WithdrawnTreatmentSalivary Gland Malignancy1
2, 3Active Not RecruitingTreatmentColorectal Cancers1
3Active Not RecruitingTreatmentEsophageal Squamous Cell Cancer1
3Active Not RecruitingTreatmentHead and Neck Carcinoma1
3Active Not RecruitingTreatmentInfiltrating Urothelial Carcinoma / KRAS Gene Mutation1
3Active Not RecruitingTreatmentMetastatic Colorectal Cancers1
3CompletedTreatmentColorectal Cancers1
3CompletedTreatmentColorectal Cancers / Metastases1
3CompletedTreatmentMetastatic Colorectal Cancers3
3Not Yet RecruitingTreatmentColorectal Adenocarcinoma / RAS Wild Type / Stage III Colorectal Cancer AJCC v7 / Stage IIIA Colorectal Cancer AJCC v7 / Stage IIIB Colorectal Cancer AJCC v7 / Stage IIIC Colorectal Cancer AJCC v7 / Stage IV Colorectal Cancer AJCC v7 / Stage IVA Colorectal Cancer AJCC v7 / Stage IVB Colorectal Cancer AJCC v71
3Not Yet RecruitingTreatmentMetastatic Colorectal Cancers1
3RecruitingTreatmentNeoplasms, Colorectal1
3TerminatedTreatmentOesophago-gastric Cancer1
3Unknown StatusTreatmentColorectal Cancers1
3WithdrawnTreatmentHead and Neck Carcinoma1
4RecruitingHealth Services ResearchMalignant Neoplasm of Colon / Unresectable Metastasis Originating in Colonic Cancer1
4RecruitingTreatmentCancers1
Not AvailableCompletedNot AvailableAdvanced or Recurrent Colorectal Cancer1
Not AvailableCompletedNot AvailableMetastatic Colorectal Cancers1
Not AvailableRecruitingNot AvailableMetastatic Colorectal Cancers / RAS Wild-type1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Injection, solution, concentrateIntravenous20 mg/ml
SolutionIntravenous100 mg/5mL
SolutionIntravenous100 mg
SolutionIntravenous200 mg/10mL
SolutionIntravenous200 mg
SolutionIntravenous400 mg/20mL
SolutionIntravenous400 mg
Prices
Unit descriptionCostUnit
Vectibix 400 mg/20ml Solution 20ml Vial4349.4USD vial
Vectibix 100 mg/5ml Solution 5ml Vial1059.24USD vial
Vectibix 100 mg/5 ml vial203.7USD ml
Vectibix 200 mg/10 ml vial203.7USD ml
Vectibix 400 mg/20 ml vial203.7USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Suppressor
General Function
Ubiquitin protein ligase binding
Specific Function
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TG...
Gene Name
EGFR
Uniprot ID
P00533
Uniprot Name
Epidermal growth factor receptor
Molecular Weight
134276.185 Da
References
  1. Lynch DH, Yang XD: Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment. Semin Oncol. 2002 Feb;29(1 Suppl 4):47-50. [PubMed:11894013]
  2. Cohen RB: Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer. 2003 Feb;2(4):246-51. [PubMed:12620146]
  3. Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, Rowinsky EK, Dutcher JP, Vogelzang NJ, Gollub J, Thompson JA, Schwartz G, Bukowski RM, Roskos LK, Schwab GM: Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90. [PubMed:14967460]
  4. Segaert S, Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005 Sep;16(9):1425-33. Epub 2005 Jul 12. [PubMed:16012181]
  5. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R: Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4441s-4445s. [PubMed:16857825]
  6. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG: Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol. 2001 Apr;38(1):17-23. [PubMed:11255078]
  7. Keating GM: Spotlight on panitumumab in metastatic colorectal cancer. BioDrugs. 2010 Aug 1;24(4):275-8. doi: 10.2165/11205460-000000000-00000. [PubMed:20623992]
  8. Wu M, Rivkin A, Pham T: Panitumumab: human monoclonal antibody against epidermal growth factor receptors for the treatment of metastatic colorectal cancer. Clin Ther. 2008 Jan;30(1):14-30. doi: 10.1016/j.clinthera.2008.01.014. [PubMed:18343240]
  9. Saadeh CE, Lee HS: Panitumumab: a fully human monoclonal antibody with activity in metastatic colorectal cancer. Ann Pharmacother. 2007 Apr;41(4):606-13. Epub 2007 Mar 13. [PubMed:17355997]
  10. Jean GW, Shah SR: Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy. 2008 Jun;28(6):742-54. doi: 10.1592/phco.28.6.742. [PubMed:18503402]
  11. Keating GM: Panitumumab: a review of its use in metastatic colorectal cancer. Drugs. 2010 May 28;70(8):1059-78. doi: 10.2165/11205090-000000000-00000. [PubMed:20481659]
  12. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on May 16, 2007 14:12 / Updated on December 10, 2017 17:18